Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Corneal Neovascularization
NCT01501760Phase 3Completed
- Sponsor
- CHU de Limoges
- Start
- May 2012
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in corneal neovascularization (CNV), sponsored by CHU de Limoges. Started May 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on NCT01501760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01501760.